Anti-nicotine abuse vaccines in the pipeline: an update.

Abstract

Three different companies have completed Phase II clinical studies of their anti-nicotine vaccines and are rushing to obtain regulatory approval and to bring their vaccine candidates to the market. The vaccines are composed of the nicotine molecule linked to a carrier protein and an adjuvant. The results in all three clinical studies are encouraging… (More)
DOI: 10.1517/13543784.17.5.691

Topics

  • Presentations referencing similar topics